Astana Biomed Group, an authorized Abcam distributor in Central Asia

Anti-HTF9C/TRMT2A antibody [EPR16485-54] - BSA and Azide free (ab251437)

Key features and details

  • Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
  • Rabbit monoclonal [EPR16485-54] to HTF9C/TRMT2A - BSA and Azide free
  • Suitable for: WB, IP, IHC-P
  • Knockout validated
  • Reacts with: Mouse, Rat, Human

Overview

  • Product name

    Anti-HTF9C/TRMT2A antibody [EPR16485-54] - BSA and Azide free
    See all HTF9C/TRMT2A primary antibodies

  • Description

    Rabbit monoclonal [EPR16485-54] to HTF9C/TRMT2A - BSA and Azide free

  • Host species

    Rabbit

  • Tested applications

    Suitable for: WB, IP, IHC-Pmore details

  • Species reactivity

    Reacts with: Mouse, Rat, Human

  • Immunogen

    Recombinant fragment. This information is proprietary to Abcam and/or its suppliers.

  • Positive control

    • WB: HeLa and MOLT-4 cell lysates.

  • General notes

    ab251437 is the carrier-free version of ab205616 This format is designed for use in antibody labeling, including fluorochromes, metal isotopes, oligonucleotides, enzymes.

     

    Our carrier-free formats are supplied in a buffer free of BSA, sodium azide and glycerol for higher conjugation efficiency.

    Use our conjugation kits  for antibody conjugates that are ready-to-use in as little as 20 minutes with

    Ab251437 is compatible with the Maxpar® Antibody Labeling Kit from Fluidigm.

    Maxpar® is a trademark of Fluidigm Canada Inc.

    This product was previously labelled as HTF9C

    This product is a recombinant monoclonal antibody, which offers several advantages including:

    • - High batch-to-batch consistency and reproducibility
    • - Improved sensitivity and specificity
    • - Long-term security of supply
    • - Animal-free production
    For more information see here.

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.

Properties

Images

  • Western blot - Anti-HTF9C/TRMT2A antibody [EPR16485-54] - BSA and Azide free (ab251437)
    Western blot - Anti-HTF9C/TRMT2A antibody [EPR16485-54] - BSA and Azide free (ab251437)
    All lanes : Anti-HTF9C/TRMT2A antibody [EPR16485-54] (ab205616) at 1/1000 dilution

    Lane 1 : Wild-type HeLa cell lysate
    Lane 2 : TRMT2A knockout HeLa cell lysate
    Lane 3 : MOLT-4 cell lysate

    Lysates/proteins at 20 µg per lane.

    Secondary
    All lanes : Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) at 1/10000 dilution

    Predicted band size: 69 kDa
    Observed band size: 75 kDa
    why is the actual band size different from the predicted?



    This data was developed using the same antibody clone in a different buffer formulation (ab205616).

    Lanes 1-3: Merged signal (red and green). Green - ab205616 observed at 75 kDa. Red - loading control ab8245 observed at 36 kDa. 

     ab205616 Anti-HTF9C/TRMT2A antibody [EPR16485-54] was shown to specifically react with HTF9C/TRMT2A in wild-type HeLa cells. Loss of signal was observed when knockout cell line ab265160 (knockout cell lysate ab258253) was used.  Wild-type and HTF9C/TRMT2A knockout samples were subjected to SDS-PAGE.  ab205616 and Anti-GAPDH antibody [6C5] - Loading Control (ab8245) were incubated at room temperature for 2. 5 hours at 1 in 1000 dilution and 1 in 20000 dilution respectively. Blots were developed with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preadsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preadsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 hour at room temperature before imaging.

  • Anti-HTF9C/TRMT2A antibody [EPR16485-54] - BSA and Azide free (ab251437)
    Anti-HTF9C/TRMT2A antibody [EPR16485-54] - BSA and Azide free (ab251437)

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

© 2021 Astana Biomed Group LLP. All rights reserved.